213 related articles for article (PubMed ID: 24402161)
21. Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.
Tian A; Wilson GS; Lie S; Wu G; Hu Z; Hebbard L; Duan W; George J; Qiao L
Cancer Lett; 2014 Sep; 351(2):232-41. PubMed ID: 24976294
[TBL] [Abstract][Full Text] [Related]
22. Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein.
Qin Q; Zuo Y; Yang X; Lu J; Zhan L; Xu L; Zhang C; Zhu H; Liu J; Liu Z; Tao G; Dai S; Zhang X; Ma J; Cai J; Sun X
Tumour Biol; 2014 Mar; 35(3):2565-74. PubMed ID: 24170321
[TBL] [Abstract][Full Text] [Related]
23. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis.
Guo F; Nimmanapalli R; Paranawithana S; Wittman S; Griffin D; Bali P; O'Bryan E; Fumero C; Wang HG; Bhalla K
Blood; 2002 May; 99(9):3419-26. PubMed ID: 11964312
[TBL] [Abstract][Full Text] [Related]
24. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells.
Roa WH; Chen H; Fulton D; Gulavita S; Shaw A; Th'ng J; Farr-Jones M; Moore R; Petruk K
Clin Invest Med; 2003 Oct; 26(5):231-42. PubMed ID: 14596484
[TBL] [Abstract][Full Text] [Related]
25. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S
Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226
[TBL] [Abstract][Full Text] [Related]
27. Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer.
Zeng C; Vangveravong S; McDunn JE; Hawkins WG; Mach RH
Br J Cancer; 2013 Oct; 109(9):2368-77. PubMed ID: 24104966
[TBL] [Abstract][Full Text] [Related]
28. Smac mimetic‑induced caspase‑independent necroptosis requires RIP1 in breast cancer.
Jin G; Lan Y; Han F; Sun Y; Liu Z; Zhang M; Liu X; Zhang X; Hu J; Liu H; Wang B
Mol Med Rep; 2016 Jan; 13(1):359-66. PubMed ID: 26573429
[TBL] [Abstract][Full Text] [Related]
29. Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug- Resistant Cells.
Jin G; Wang K; Liu Y; Liu X; Zhang X; Zhang H
Anticancer Agents Med Chem; 2020; 20(6):687-699. PubMed ID: 32053082
[TBL] [Abstract][Full Text] [Related]
30. Induction of interferon-β and interferon signaling by TRAIL and Smac mimetics via caspase-8 in breast cancer cells.
Granqvist V; Holmgren C; Larsson C
PLoS One; 2021; 16(3):e0248175. PubMed ID: 33770100
[TBL] [Abstract][Full Text] [Related]
31. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.
Fandy TE; Shankar S; Ross DD; Sausville E; Srivastava RK
Neoplasia; 2005 Jul; 7(7):646-57. PubMed ID: 16026644
[TBL] [Abstract][Full Text] [Related]
32. [Effects of LCL161, a Smac mimetic on the proliferation and apoptosis in hepatocellular carcinoma cells].
Ren K; Ma L; Chong D; Zhang Z; Zhou C; Liu H; Zhao S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Sep; 41(9):898-904. PubMed ID: 27640787
[TBL] [Abstract][Full Text] [Related]
33. Induction of Necroptosis in Human Breast Cancer Drug-Resistant Cells by SMAC Analog LCL161 After Caspase Inhibition Requires RIP3.
Jin G; Liu Y; Xu P; Jin G
Pharmazie; 2019 Jun; 74(6):363-368. PubMed ID: 31138375
[TBL] [Abstract][Full Text] [Related]
34. Platycodin D inhibits proliferation, migration and induces chemosensitization through inactivation of the NF-κB and JAK2/STAT3 pathways in multiple myeloma cells.
Wu D; Zhang W; Chen Y; Ma H; Wang M
Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1194-1200. PubMed ID: 31347196
[TBL] [Abstract][Full Text] [Related]
35. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells.
Siegmund D; Klose S; Zhou D; Baumann B; Röder C; Kalthoff H; Wajant H; Trauzold A
Cell Signal; 2007 Jun; 19(6):1172-84. PubMed ID: 17291719
[TBL] [Abstract][Full Text] [Related]
36. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis.
Kim HS; Chang I; Kim JY; Choi KH; Lee MS
Cancer Res; 2005 Jul; 65(14):6111-9. PubMed ID: 16024612
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
38. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
39. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
40. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM
Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
